Lifeward Ltd.
LFWDHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeLifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and. Valued at $19.8M, LFWD is a micro-cap name in its sector. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke.
Market Cap
$19.8M
Beta
0.40
P/E (TTM)
—
P/E (Fwd)
-8.12
EPS (TTM)
$-14.66
EPS (Fwd)
$-0.86
ROE
-225.7%
ROA
-47.3%
Cash
$9.4M
Total Debt
$7.0M
Free CF
-$8.0M
52W Change
4.0%
Annual Financials
Cash vs Debt
Where LFWD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LFWD finished 3.57% above its 150-day moving average ($7.01) and 1.11% above its 200-day moving average ($7.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFWD overbought or oversold?
At the September 3, 2026 close, LFWD's RSI(14) was 33.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $9.4M in cash and $7.0M in debt, LFWD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$8.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -225.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5.5M (2022) to $22.0M (2025), reflecting a 300% increase over the period.
The relatively low beta of 0.40 suggests LFWD is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Lifeward Ltd. and its sector.